|
Our lead infectious disease product candidate is ImmunoVEXHSV2,
a vaccine for genital herpes.
At least 45 million people over
the age of 11 in the United States have been infected with HSV-2,
the cause of genital herpes, according to the Centers for Disease
Control and Prevention. However, even though a number of HSV-2
vaccine candidates have previously been developed, none has proved
to be broadly effective. ImmunoVEXHSV2 is a novel live-attenuated
vaccine candidate based on the novel concept of removing genes
responsible for immune evasion and is therefore intended to stimulate
a broad and powerful immune response.
In preclinical studies, ImmunoVEXHSV2 completely
prevented disease and invoked a powerful immune response, suggesting
that ImmunoVEXHSV2 may be more potent than other HSV-2 vaccines for
which published data are available. We intend
to initiate a Phase I clinical trial for this product candidate
in the first half of 2008 and to report initial data in the first
half of 2009.
top
|
